Form 425 D8 Holdings Corp. Filed by: D8 Holdings Corp. –

silogo new ProxyEgg Form 425 D8 Holdings Corp. Filed by: D8 Holdings Corp. -

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Filed by D8 Holdings Corp.

pursuant to Rule 425 under the
Securities Act of 1933

and deemed filed pursuant to
Rule 14a-12

under the Securities Exchange
Act of 1934

Subject Company: D8 Holdings

Commission File No. 333-257055

Date: August 17, 2021


On August 12, 2021, Adam Sachs, the Co-founder
and Chief Executive Officer of Vicarious Surgical Inc., Bill Kelly, the Chief Financial Officer of Vicarious Surgical Inc., David Styka,
the Executive Chairman of Vicarious Surgical Inc., and Donald Tang, the President of D8 Holdings Corp., participated in an interview with
Kyle Rose at the Canaccord Genuity 41st Annual Growth Conference. A copy of the transcript of the interview is set forth below:


<<Kyle Rose, Interviewer>>

Good morning everyone and thank you for joining
us at the 41st Annual Canaccord Genuity Global Growth Conference. My name is Kyle Rose. I am one of the medical technology analysts here
at Canaccord Genuity, and I’m excited to be joined this morning by Vicarious Surgical. It was a next-generation surgical robotics company,
which focused on developing a differentiated platform for robotic surgery, the goal of improving outcomes as well as reducing costs. With
me this morning are Donald Tang, President of D8 Holdings; as well as Adam Sachs, the Co-Founder and CEO of Vicarious; and Bill Kelly,
the CFO of Vicarious. Thank you all for joining us this morning. So we’re going to do a presentation here, but before we start I need
to remind everybody of any relevant disclosures. If and where applicable and you can find those on either our conference and/or our firm

And with that, I’ll turn it over to the Vicarious
team to start the presentation. Thank you very much.

<<Donald Tang, President, D8 Holdings Corp.>>

Good morning. Thanks for the time. I am Donald
Tang. I’m Director and President of D8 Holdings, based in Hong Kong. I am a private equity investor, also a SPAC sponsor, and of
course, D8 Holdings is pursuing a combination with Vicarious Surgical. Also on the call, as mentioned, Adam Sachs, Co-Founder and CEO
of Vicarious Surgical; David Styka, Executive Chairman; and Bill Kelly, CFO.

So, why Vicarious Surgical? Well, we prepared
a short video today and I think you’ll see very clearly for yourself.

[Video Presentation Starts]

At Vicarious Surgical, we are connecting advanced
miniature robotics, computer science, and 3D visualization to build a new category of intelligence and affordable single incision surgical
robots. Miniaturization is part of our core philosophy, and that starts with just one small incision. The entire Vicarious robot fits
into the patient’s abdomen through a single port. Once inserted the miniature camera and arms are precisely configured for surgeon control.
Standard laparoscopic tools are straight with limited dexterity, some robotic tools improve upon this by adding risks. Vicarious instruments
redefine robotic motion with fully articulating risks, elbows and shoulders. Movement feels natural while providing precise control and
the unique ability to grasp or dissect using any surgical approach. This advanced design enables the robot to rotate and reorient in any
direction. This gives surgeons the unprecedented ability to work downward, sideways as well as up and even backward relative to the incision
site with just one simple incision to open and close. Vicarious streamlines trocar placement and accelerates procedures.

The Vicarious robots can approach the same target
from any angle with trocar centered motion. This multi-access motion capability enables the robots to be repositioned anywhere throughout
the abdomen. With versatile trocar placement, the entire abdomen has accessible. Vicarious combines its miniaturized ultra-high definition
camera and robotic arms with virtual reality to unlock an unprecedented model of human-computer interaction. Moving the camera is as natural
as turning your head. This immersive 3D visualization is paired with precision hand controllers designed to mimic open instruments with
nearly weightless ergonomic control. The result is a user experience where the surgeon feels transported inside the patient.

The Vicarious system has just two parts: the versatile
robotic pedestal and the VR console featuring an ancillary display. Both units are compact and portable taking up less than half the space
and costs of existing robotics solutions. This efficient system design enables easy access around the patient, improves workflow and saves
valuable OR time. The Vicarious platform is cost-effective and easy to integrate, making it accessible to all operating rooms, community
hospitals and surgical centers. With a system instrument and for advanced sensing, data collection and artificial intelligence surgeons
will be able to avoid errors, measure anything instantly and suture automatically, creating a future where everyone has access to the
latest surgical innovations, Vicarious Surgical.

[Video Presentation Ends]

<<Donald Tang, President, D8 Holdings Corp.>>

So we look at more than a hundred companies as
potential targets for D8 and the reality is Vicarious Surgical simply blew us away. It checks all the boxes in what we look for in a business
combination. It’s a visionary team backed by the savviest investors behind disruptive technologies, a massive TAM will be addressed by
legacy solutions that only scratch the surface of what’s possible today and of course the product that’s loved by surgeons and hospitals
designed specifically around existing limitations.

We also like the fact that there’s de-risked path
for commercialization – the breakthrough designation from the FDA. And most importantly of being based in Asia, this is a business
that we can actually help accelerate, not just with capital, but also with relationships and the ability to build businesses in the region.
So we did our diligence and brought on partner advisors and the truth is all surgeons I spoke to were simply […] and the robotics
capabilities. So very quickly we locked down the transaction what’s being presented today as a result of that.

With that David Styka will introduce the rest
of the team.

<<David Styka, Executive Chairman, Vicarious
Surgical Inc.>>

Hi, good morning. My name is David Styka. I’m
Executive Chairman of Vicarious Surgical. I joined in late 2020. I spent the last 30 years of my career working with innovative startups,
the last 20 years in healthcare. In particular, since 2014, I’ve been focused on the robotic surgery sector as CFO of Auris Health. At
Auris, I have partnered with our founder Dr. Fred Moll, leading innovator in surgical robotics and co-founder of Intuitive Surgical and
developing next generation robotic platforms. The results of our efforts over the five years, I was there, was $5.7 billion acquisition,
including earnouts by Johnson & Johnson in 2019.

Over those five years, I had the privilege to
see the latest advancements in robotic medical technology. Nothing I saw during my tenure rivals the unique architecture of the platform
that Vicarious is developing today. This is truly disruptive technology that has the opportunity to improve medical outcomes across a
large – a swath of medical procedures. The Co-Founder, Adam Sachs – the Co-Founders, Adam Sachs, who is on the call and Sammy
Khalifa have – exceptionally talented team that has the expertise to exploit this opportunity. And with the additions of June Morris
as our General Counsel; and Bill Kelly, as CFO, who is also on the call is well equipped to become a public company. I’m truly excited
about this opportunity, couldn’t wait to join. It’s my great pleasure to be part of it.

With that, let me turn it over to Adam, to dive
deeper into the company and the technology.

<<Adam Sachs, Co-Founder and Chief Executive
Officer, Vicarious Surgical Inc.>>

Thanks, David, and thanks to everybody for setting
this up as well as for making the time today. So I’m Adam Sachs. I’m the founding CEO here at Vicarious Surgical. I’m a roboticist by
training. I studied at MIT, same as Sammy, that’s where we met. And we worked at Apple for a brief stint afterward, but pretty quickly
decided to leave and pursue our passion for medical devices and start this company with our third Co-Founder Dr. Barry Greene.

Since then I’ve had the privilege of being joined
by an incredible leadership team, as well as some amazing investors, true visionaries from this space of Bill Gates, Vinod Khosla, Eric
Schmidt, Jerry Yang, E15 Capital and incredible advisors, not only David by also Paul Hermes, who ran the entire Medtronic Robotics Program,
and Dave Hyatt, who is GC and Chief IP Counsel at Becton Dickinson.

So before diving into the details of what we’re
doing, I’d love to take just a slide or two and cover the world of surgery as it exists today. And it, of course, starts with open surgical
procedures. For the open surgery, a surgeon will take a scalpel quite literally, open up the patient’s abdomen, see with their own eyes,
operate with their own hands, but the incision itself causes a 20% complication rate that results in the need for additional surgery to
correct. And that’s what minimally invasive surgery is all about, making three to five small incisions that drive complications from 20%
down to 1% for the patient, but vastly increased complexity for the surgeon. The motion all now pivots about the abdominal wall, and even
with legacy surgical robots, which have a wrist inside of the abdomen, they’re still stuck with their primary motion created based on
where the surgeon wants to operate inside the abdomen and where do they chose to make incisions in the abdominal wall.

What that means to me as a roboticist is that
for a legacy surgical robot, the surgeon actually defines the robotic motion, the kinematics for every procedure based on where they choose
to put the incisions and where they wanted to operate. So in order to get away from these challenges, there have been robotic attempts
at single port surgery. These systems use flexible robotic technology, creating motion all through one incision so that they get past
the abdominal wall. But with those flexible robots, they all have this impossible to solve the challenge of being both too small once
they’re inside with too low force, as well as two big going in through incisions that are 2.5 centimeters or greater starting to approach
complication rates of open surgery with less capability than minimally invasive surgery.

So, of course, the question is where does all
of this leave us two decades into robotics, four decades in the minimally invasive surgery? And the answer is we’re still performing mostly
open surgery with these large incisions. There are a lot of reasons for this, but it really comes down to high cost as well as difficult,
the abuse, because the surgeon needs to define that kinematic profile, they need to actually book OR time and perform over a hundred procedures
in order to gain proficiency with a legacy robot. All of this plus limited capability has led to low utilization and incredible white
space and opportunity for us with only 3.2% of addressable procedures being performed with robots today, less than 1% of all procedures.

So to really get past this, to drive real meaningful
utilization in surgical robotics, we need a solution that really addresses all of these needs of the patient, the surgeon, the hospital,
and the payer. So, of course, that brings us to what we’re doing at Vicarious Surgical. When we started this company seven years ago,
we had this vision of essentially creating an avatar of the surgeon inside the abdomen all through one incision, but we pretty quickly
realized that the robotic technology to do so simply did not exist at the time. Flexible robots, I explained, are both too small and too
low force, but require too big an incision and rigid robots wrists on a stick that exists in operating rooms today. They have something
called coupled motion. So every joint that you move within a legacy surgical robot actually moves the other joints. And you end up needing
to use complex, coordinated motion to produce simple motions of just one joint in the end effector.

And while that works, the problem that can’t be
solved is that it leads to this exponential build-up of force, joint by joint near doubling of force as you go through the arm. That’s
why with just three joints, “just a wrist on a stick” legacy robots need 1 millimeter diameter control cables and those cables
end up snapping still in a couple percent of cases due to the high loads. We’ve invented and spent the last seven years developing a series
of ways to decouple that motion, allowing us to fit nine joints on – per arm on two arms, plus a camera all through a 1.5 centimeter
incision, a normal laparoscopic incision. You can see in the center of the slide, how much smaller that is than today’s single port robots,
but once it’s inside, it has incredible capability. Those nine degrees of freedom represent wrists, elbows, and shoulders.

Everybody else in the industry focuses on seven
degrees of freedom, six degrees plus an end effector, but we’ve actually enabled the same redundant joints that a human has just like
the surgeon can move their elbow up and down while keeping their hands still approach things from different angles to avoid interference.
The surgeon’s avatar can inside the patient with our robot. And beyond that we have superhuman flexibility. The surgeon can not only turn
left, right, up, down, they can reach all the way back around the incision site, letting them work anywhere in the abdomen.

With all this capability inside the abdomen, the
system outside is now a small non-robotic support system [and] is portable [which can be] moved from OR to OR. Once it’s inserted, the
surgeon can work anywhere from any incision site facing in any direction. We’re no longer doing chip on a stick. The entire sensing system
is built into this incredible platform inside the abdomen, designed by our AI team in order to enable the future of automating simple
surgical tasks. We have 3D mapping in real-time as well as force sensing and physician sensing from every joint inside the body provided
by 28 sensors in each of these arms. That gives haptic feedback, ability to set limits and a lot of future potential for our AI team.

And finally those same decoupled actuators provide
incredible economic benefits. It’s the fact that the forces are so much lower combined with fact that those decoupled actuators allow
us to use slippery polymer cables. They’re slippery as wet ice on wet ice, but as stiff as aluminum. And that allows us to use almost
entirely polymer parts in our system allowing us to do a fully disposable sterile portion of the robot at a competitive price. And last
but not least the capital equipment is no longer 4 gigantic robotic arms. It’s one small non-robotic support system that has the cost
[…] that’s conservatively 5x to 10x lower than what exists today.

So we’ve taken this to 20 surgeons plus 20 hospital
administrators in a blinded market research study run by a leading firm in the industry. The results were incredible, and the features
that surgeons and hospitals love are the features that are unique to that technology to those decoupled actuators, that ability to reach
anywhere from any incision site facing in any direction, the wrists, elbows and shoulders, plus the visualization to match, we were ranked
4.8 out of five, again, legacy minimally invasive surgery 4.2 out of 5, again legacy surgical robots 95th percentile for any study run
by this firm and puts us squarely in that major breakthrough category. Of course, the FDA recognizes the breakthrough here as well. We
are the only robotic platform to receive a breakthrough designation from the agency. And with that, they provide prioritized review, a
de-risked pathway and reimbursement benefits on market.

So we’ve outlined a path to get us from where
we are today through FDA filing in 2023 generating strong news flow across four categories: development, regulatory, commercial and growth.
We have an incredible internal regulatory team, some amazing external advisors and FDA counsel, all of whom have cleared surgical robots
through the FDA. And they’ve developed a high competence pathway by focusing on a single indication first and then an expansion strategy
after that with additional clearances. So that first indication is ventral hernia repair, which we are using as a stepping stone to the
rest of the market, but it’s an incredible indication in itself. There are almost a million ventral hernias every year in the United States
alone, 40% of these never repaired, the remainder repaired primarily with simple hernia repair techniques, where a non-adhesive mesh is
adhered to the non-adhesive peritoneum, they don’t successfully stick 20% of the time resulting in recurrence of the hernia.

There is better – a better way to do this,
complex abdominal wall repairs, where you make six to eight incisions, insert legacy robots from both sides of the patient, dissect down
flaps in the abdominal wall and tuck an uncoated mesh against the rectus muscle in order to allow scar tissue formation into the mesh.
This provides a much more robust repair driving recurrence from 20% down to 4%. Reimbursement is much higher under existing coding, but
it takes over four hours to perform with a legacy robot.

We’ve proven out the ability to do the same thing,
to do that same technique with a single 15 millimeter, 1.5 centimeter incisions single docking in under two hours, actually, since we’ve
got the breakthrough, we’ve done it successfully in under one hour, generating 5x better outcomes over twice the reimbursement decreased
procedural time all in a huge market. And this is what really want is a breakthrough designation. That being said it is, of course, just
a stepping stone to the rest of the market after ventral hernia will be filing for procedure after procedure, clearance after clearance,
indication after indication. And we’ll be able to address within a few years the majority of abdominal procedures.

So with that, and only three minutes remaining,
I believe if I’m keeping track of time correctly, I’ll turn it over to Bill, who will walk through the modeling projections.

<<William J. Kelly, Chief Financial Officer,
Vicarious Surgical Inc.>>

Sorry. Yes, so thank you, Adam. I appreciate it.
First of all, the board is extremely excited about this company, the technology, the transaction that really has the ability to be truly
transformative. And what I mean by that is it allows us to complete our final development get through all of our regulatory and clinical
activities and successfully launch commercial operations of this exciting technology so we can get it on the market.

We’re launching in 2023 with breakthrough designation
and given the size of the market opportunity, as well as the strong competitive advantages that we’ve talked about with price, size, functionality,
capability, ease of use, fast throughput, all those factors and then as well as that – the significant cost advantages that we have,
the disposability of the sterile components, the design of the overall system using processes and technologies that in many cases were
not available 20 years ago when legacies – many legacy systems were being developed, all those factors allow us to deliver we believe
the revenue and gross margin profile that you see here.

Now, our revenues start with systems predominantly,
and then as increased clinical applications come online and utilization picks up, the disposables and support components become a much
greater percentage of our total revenue profile. And so while we’ve assumed a very modest utilization, we actually think our adoption
is going to be quite strong. And that being said, given the size of the market opportunity with less than 1% penetration in our addressable
market, five years after launch and seven years from today. We believe we’re poised to deliver over $1 billion worth of revenue by 2027.
So in summary, what we have is an incredible technology. We’re attacking a large, relatively unpenetrated market with huge opportunity
for growth and great margins. And now with this transaction, we believe we’re poised to deliver significant value and we’re very excited
to share that with you.

So, with that, I thank all of you for your time.
We would love the opportunity to speak further, please reach out to the company at [email protected], or to our IR firm, Gilmartin
Group as well. Happy to talk further.

<<Kyle Rose, Interviewer>>

Great. Thank you very much for the presentation
this morning. It was very interesting and I look forward to learning more in the future.


Additional Information About the Proposed Business Combination and
Where to Find It

The proposed business combination will be submitted
to shareholders of D8 Holdings Corp. (“D8 Holdings”) for their consideration. D8 Holdings has filed a registration statement
on Form S-4 (the “Registration Statement”) with the SEC, which includes a definitive proxy statement that was distributed
to D8 Holdings’ shareholders in connection with D8 Holdings’ solicitation for proxies for the vote by D8 Holdings’ shareholders
in connection with the proposed business combination and other matters as described in the Registration Statement, as well as the prospectus
relating to the offer of the securities to be issued in connection with the completion of the proposed business combination. The Registration
Statement was declared effective on August 9, 2021 and D8 Holdings mailed the definitive proxy statement and other relevant documents
to its shareholders as of the record date established for voting on the proposed business combination. D8 Holdings’ shareholders
and other interested persons are advised to read the definitive proxy statement/prospectus in connection with D8 Holdings’ solicitation
of proxies for its extraordinary general meeting of shareholders to be held to approve, among other things, the proposed business combination,
because these documents contain important information about D8 Holdings, Vicarious Surgical Inc. (“Vicarious Surgical”) and
the proposed business combination. Shareholders may also obtain a copy of the definitive proxy statement/prospectus, as well as other
documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by D8 Holdings, without
charge, at the SEC’s website located at or by directing a request to D8 Holdings, at Unit 1008, 10/F, Champion Tower, 3 Garden
Road, Central, Hong Kong.

Participants in the Solicitation

D8 Holdings, Vicarious Surgical and certain of
their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants
in the solicitations of proxies from D8 Holdings’ shareholders in connection with the proposed business combination. Information
regarding the persons who may, under SEC rules, be deemed participants in the solicitation of D8 Holdings’ shareholders in connection
with the proposed business combination is set forth in the Registration Statement and the definitive proxy statement/prospectus. You can
find more information about D8 Holdings’ directors and executive officers in D8 Holdings’ Annual Report on Form 10-K/A, filed
with the SEC on May 24, 2021. Additional information regarding the participants in the proxy solicitation and a description of their direct
and indirect interests is included in the Registration Statement and the definitive proxy statement/prospectus and other relevant documents
filed with the SEC. Shareholders, potential investors and other interested persons should read the definitive proxy statement/prospectus
carefully before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

Forward-Looking Statements

The information in this communication includes
“forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,”
“project,” “forecast,” “intend,” “will,” “expect,” “anticipate,”
“believe,” “seek,” “target” or other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements
regarding estimates and forecasts of financial and performance metrics and expectations and timing related to potential benefits, terms
and timing of the transaction. These statements are based on various assumptions, whether or not identified in this communication, and
on the current expectations of Vicarious Surgical’s and D8 Holdings’ management and are not predictions of actual performance.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied
on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances
are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of
Vicarious Surgical and D8 Holdings. These forward-looking statements are subject to a number of risks and uncertainties, including changes
in domestic and foreign business, market, financial, political, and legal conditions; the inability of the parties to successfully or
timely consummate the proposed business combination, including the risk that any required approvals are not obtained, are delayed or are
subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business
combination or that the approval of the shareholders of D8 Holdings or Vicarious Surgical is not obtained; failure to realize the anticipated
benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to
Vicarious Surgical; future global, regional or local economic and market conditions; the development, effects and enforcement of laws
and regulations; Vicarious Surgical’s ability to manage future growth; Vicarious Surgical’s ability to develop new products
and solutions, bring them to market in a timely manner, and make enhancements to its products; the effects of competition on Vicarious
Surgical’s future business; the amount of redemption requests made by D8 Holdings’ public shareholders; the ability of D8
Holdings or the combined company to issue equity or equity-linked securities in connection with the proposed business combination or in
the future; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors
discussed in the Registration Statement under the heading “Risk Factors,” and the other documents filed, or to be filed, by
D8 Holdings with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There may be additional risks that neither Vicarious Surgical nor D8 Holdings
presently know or that Vicarious Surgical and D8 Holdings currently believe are immaterial that could also cause actual results to differ
from those contained in the forward-looking statements. In addition, forward-looking statements reflect Vicarious Surgical’s and
D8 Holdings’ expectations, plans or forecasts of future events and views as of the date of this communication. Vicarious Surgical
and D8 Holdings anticipate that subsequent events and developments will cause Vicarious Surgical’s and D8 Holdings’ assessments
to change. However, while Vicarious Surgical and D8 Holdings may elect to update these forward-looking statements at some point in the
future, Vicarious Surgical and D8 Holdings specifically disclaim any obligation to do so. These forward-looking statements should not
be relied upon as representing Vicarious Surgical’s and D8 Holdings’ assessments as of any date subsequent to the date of
this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.


No Offer or Solicitation

This communication does not constitute an offer
to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale
of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements
of Section 10 of the Securities Act, or an exemption therefrom.


Source of this news:

Related posts:

More In-Person Scouting Looks, Headlined by Frankie Montas' Sim Game - Fangraphs
Gary A. Vasquez-USA TODAY Sports Frankie Montas was a late scratch from his Saturday start and instead, on Sunday, threw in an early-morning sim game on Oakland’s backfields. Opposing scouts in atten...
Life of a Packet through Istio -
Transcript Turner: Hopefully I've got the three hours done enough because I know I stand between you and beer. You've had literal Google tell you about how they literally invented microservices and t...
Chinese APT group IronHusky exploits zero-day Windows Server privilege escalation - Reseller News
Credit: Dreamstime One of the vulnerabilities patched by Microsoft has been exploited by a Chinese cyber-espionage group since at the least August. The attack campaigns targeted IT companie...
Amazon Prime Video VPN error still troubling users despite being fixed - PiunikaWeb
Amazon Prime Video is among the top streaming services across the globe. It is offered both as part of the Prime subscription and a standalone service. While Prime Video has a pretty decent user base...
Zenscrape Web Scraping and Extraction API at Scale - XDA Developers
Web scraping on a large scale doesn’t have to be a complicated and frustrating task. Some of the more common hurdles that people have to jump through when scraping through data are IP bans and scalab...
The way you can Fix 'PUBG Mobile Hosting is Busy' Issue rapid BollyInside
This behavior tutorial is about the How one can Fix ‘PUBG Mobile Hardware is Busy’ Issue. Heading to try our best so that you understand this manual. I hope you like this blog How to Deal with ...
Best ways to secure your information from breaches in 2022 - Craving Tech
Photo by Joshua Sortino on UnsplashNote: This is a guest post written by Dan MartinData breaches continue to be a threat to both individuals and organizations. Hackers are becoming innovative in how ...
Berkshire Grey Unveils Next Generation of Intelligent Enterprise Robotic Picking and Advanced Mobili...
BEDFORD, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Berkshire Grey, the leader in AI-enabled robotic solutions that automate supply chain processes, launched the next generation of Intelligent Enterpri...
Eugenio Suárez Needs More Power - FanGraphs
Eugenio Suárez is not a major league caliber shortstop. That’s no knock on him — pretty much no one in the entire world is, and he picked the position up out of necessity rather than because it was i...
Wikipedia bans Chinese editors, pro-Beijing editors call it ‘well-calculated suppression’ - ThePrint
Wikipedia is a free online encyclopedia edited by volunteers while hosted by the Wikimedia Foundation support. Text Size: A- A+ New kinds of Delhi:   The Wikimedia Foundation m...
Very good Technologies Upgrades Network Invasion Discovery Solution To Identify 33 New Types of Susp...
Positive Technologies released version 10. 2 of its PT Network Challenge Discovery (PT NAD) visitor analysis system, which recognizes attacks on the perimeter or inside corporate networks, manufac...
Bepi Ghiotti - 'An artwork is never still although what it represents might seem like it is' - Artsp...
If we can argue that artists work with intangibles, then we could perhaps also say that Bepi Ghiotti’s chosen medium is time. The Italian artist was born in 1965 and can remember first taking an inte...
Lyceum APT Returns, This Time Aiming for Tunisian Firms - Threatpost
This administrator of your personal knowledge will be Threatpost, Inc., 900 Unicorn Park, Woburn, EPPURE 01801. Detailed information on the very processing of personal data can be found in the ...
NexuStorage says blocks and files can come from object storage – Blocks and Files - Blocks and Files
NexuStorage’s Nexfs software serves block and file data from an object-backing store using sub-file chunking to reduce data movement and help data tiering, and claims great tier-one storage cost savi...
Transitions: Eric Cantrell, 7thSense - InPark Magazine
Interview by Jordan Zauha Eric Cantrell has worked for show control solutions company Medialon since 2008. Founded in 1992, Medialon was acquired by imaging technology company Barco in 2016, and subs...
Hiddenwires Magazine - HiddenWires
21/07/2021 Silvair has released the new custom Bluetooth mesh specification for the EnOcean Switch Mesh Proxy Server model, enabling EnOcean self-powered switches to be used together with Bluetoo...
How to Create a Proxy Server (2021) - Alphr
Proxy servers are beneficial because they act as mediators between your computer and the internet. They make online requests for you, and then they return the requested information. If you want to cr...
Direct: Install Visual Studio Code unlockerfree code|Code calculatordecoder} Extensions - Bollyinsid...
Here tutorial is about the Plan: Install Visual Studio App|Code calculatordecoder} Extensions. We will try our best which means you understand this guide. I hope you adore this blog Guide: Inst...

IP Rotating Proxy Onsale


First month free with coupon code FREE30